Ultragenyx Pharmaceutical (RARE) Research & Development (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Research & Development of $187.0 million for Q1 2026, up 12.65% year-over-year from $166.0 million in Q1 2025, and down 8.01% quarter-over-quarter from $203.3 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Research & Development (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Research & Development for 14 consecutive years, with $187.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 12.65% year-over-year to $187.0 million; the TTM figure through Mar 2026 stood at $771.2 million (up 12.5% YoY), while the FY2025 annual figure was $750.0 million, up 7.45% from the prior year.
- Research & Development fell to $187.0 million in Q1 2026 per RARE's latest filing, from $203.3 million in the prior quarter.
- Across five years, Research & Development topped out at $237.3 million in Q3 2022 and bottomed at $143.2 million in Q1 2022.
- Historically, Research & Development has averaged $175.8 million across 5 years, with a median of $166.0 million in 2025.
- Annual changes were most pronounced in 2022 — Research & Development soared 109.23% — and 2023, when it plunged 33.73%.
- Ultragenyx Pharmaceutical's Research & Development stood at $170.8 million in 2022, then dropped by 6.26% to $160.1 million in 2023, then increased by 17.36% to $187.9 million in 2024, then rose by 8.18% to $203.3 million in 2025, then fell by 8.01% to $187.0 million in 2026.
- Business Quant data shows RARE's Research & Development at $187.0 million in Q1 2026, $203.3 million in Q4 2025, and $216.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 167.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 167.00 Mn |
| Mar 31, 2026 | 187.00 Mn |
| Dec 31, 2025 | 203.28 Mn |
| Sep 30, 2025 | 216.21 Mn |
| Jun 30, 2025 | 164.74 Mn |
| Mar 31, 2025 | 166.00 Mn |
| Dec 31, 2024 | 187.90 Mn |
| Sep 30, 2024 | 170.11 Mn |
| Jun 30, 2024 | 161.50 Mn |
| Mar 31, 2024 | 178.49 Mn |
| Dec 31, 2023 | 160.11 Mn |
| Sep 30, 2023 | 157.25 Mn |
| Jun 30, 2023 | 164.95 Mn |
| Mar 31, 2023 | 165.70 Mn |
| Dec 31, 2022 | 170.81 Mn |
| Sep 30, 2022 | 237.30 Mn |
| Jun 30, 2022 | 154.53 Mn |
| Mar 31, 2022 | 143.16 Mn |
| Dec 31, 2021 | 123.01 Mn |
| Sep 30, 2021 | 113.42 Mn |